ACR 2025 Vasculitis Resources | Alison Bays, MD

🔍 Search All ACR 2025 Abstracts

🔑 Key Trials & Publications

SELECT-GCA 2-Year Extension GCA

→ Abstract #0776 NEJM 2025

METOGiA Trial GCA

→ Abstract #0891

MANDARA 2-Year Extension EGPA

→ Abstract #1608 NEJM 2024

MITIGATE Subgroup Analysis IgG4-RD

→ Abstract #2020 NEJM 2024

🔬 Giant Cell Arteritis

#0776 SELECT-GCA: 2-Year Extension Results (N=428) NEJM

#0891 METOGiA: MTX vs TCZ for GCA (N=218)

#0892 TAYLO Study: Y Chromosome Loss & GCA Relapse Risk

#0738 Real World Steroid Burden & Treatment Patterns in GCA

#0740 IV vs SC Tocilizumab in GCA-Aortitis (N=196)

#2704 Complete Metabolic Response on PET/CT: GC vs GC+TCZ

#1623 Calprotectin & Vascular Injury in Clinically-Isolated Aortitis

📰 In the News

AbbVie: FDA Approves Rinvoq for GCA (Apr 2025) The Rheumatologist: Upadacitinib Approval Coverage The Rheumatologist: Advances in Giant Cell Arteritis The Rheumatologist: Ultrasound vs Temporal Artery Biopsy Debate

🔬 Eosinophilic Granulomatosis with Polyangiitis (EGPA)

#1608 MANDARA 2-Year: Efficacy on Disease Manifestations NEJM

#1769 MANDARA 2-Year: Classification of Relapses

📰 In the News

AstraZeneca: MANDARA NEJM Publication Announcement Pulmonology Advisor: Benralizumab vs Mepolizumab for EGPA

🔬 ANCA-Associated Vasculitis

Avacopan Safety

#0724 Avacopan Liver Injury Risk: Real-World Data (N=29,163)

#2519 Avacopan FAERS Disproportionality Analysis

#2507 Avacopan: WHO VigiBase Hepatic AE Analysis

#1611 Avacopan & Calprotectin in MPA/GPA with Rituximab Induction

Rituximab & B-Cell Depletion

#1766 Incomplete B-Cell Depletion in AAV on Maintenance Rituximab

#1601 Obinutuzumab in Refractory/Relapsing AAV (Case Series)

Outcomes & Prognostic Tools

#2521 DANGER Score: Mortality Predictor in AAV

Diversity & Disparities

#0720 Diversity in AAV & GCA Clinical Trials

📰 In the News

ACR Open Rheumatology: Avacopan Combined Safety Data Rheumatology Journal: Drug-Induced Liver Injury with Avacopan

🔬 IgG4-Related Disease

MITIGATE Trial & Inebilizumab

#2020 MITIGATE: Subgroup Analysis by Organ Manifestations NEJM

#1163 MITIGATE: Biomarker Analysis of Flares

Treatment & Management

#LB02 ⭐ LATE-BREAKING: Tofacitinib + GC Reduces Relapse (RCT, N=58)

#0239 Rilzabrutinib (BTK Inhibitor): Phase 2 Safety (N=27)

📰 In the News

Amgen: FDA Approves Uplizna for IgG4-RD (Apr 2025) Sanofi: Rilzabrutinib EULAR 2025 Data Healio: Rilzabrutinib Orphan Drug Designation

🔬 Other Vasculitis

IgA Vasculitis

#2699 Cutaneous IgA Vasculitis: Colchicine vs Dapsone vs GC (N=208)

Large Vessel Vasculitis Guidelines

#1627 2025 EULAR PMR & LVV Recommendations: Systematic Review